Biocept, Inc. to Present at the 103rd American Association for Cancer Research Annual Meeting on New Analytic Methods for Circulating Tumor Cell Analysis, Including SelectorTM, Ultra-Sensitive Mutation Detection Technology

Published: Apr 02, 2012

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that it will be presenting three posters at the 103rd Annual Meeting of the American Association for Cancer Research, being held in Chicago March 31 – April 4. The presentations will cover the company’s ultra-sensitive mutation detection technology, SelectorTM, which is being applied to CTC analysis and other clinical and research applications where nucleic acid analysis requires exceptional sensitivity and specificity, as well as biomarker analysis in CTCs related to breast and prostate cancer.

Back to news